Mirum’s $790M Loss Confounds Bullish Analysts

Forward-Looking Analysis

Wall Street analysts maintain a "Moderate Buy" consensus for Mirum Pharmaceuticals based on 15 recent ratings, comprising 13 buy, 1 strong buy, and 1 sell rating. The average 12-month price target stands at $143.40, implying a forecasted upside of 12.29% from the current price of $127.70. Targets range from a low of $118.00 to a high of $185.00. Recent analyst activity shows a bullish sentiment, with multiple upgrades and target increases. On July 7, 2026, Royal Bank of Canada raised its target from $142.00 to $148.00, maintaining an Outperform rating. Similarly, JPMorgan Chase boosted its target to $125.00 from $115.00 on July 2, 2026. Earlier in the year, Morgan Stanley increased its target to $150.00 on June 11, and Citizens Jmp raised its target to $146.00 on June 15. CLSA set a new target of $146.00, while TD Cowen raised its target to $145.00 on May 7. Conversely, Weiss Ratings downgraded its rating to Sell (D-) on June 23, and Leerink Partners lowered its target to $118.00 in February. Despite the downgrade, the majority of coverage from firms including Raymond James ($165.00), Evercore ($138.00), and Stifel Nicolaus ($136.00) remains positive, with Raymond James holding a Strong Buy rating. The consensus suggests moderate upside potential driven by strong institutional support and recent target hikes from major banks.

Historical Performance Review

Mirum’s 2026Q1 results showed significant volatility. Revenue reached $159.88 million, demonstrating commercial traction. However, the company reported a substantial net loss of $-790.15 million, resulting in an EPS of $-13.43. Gross profit was recorded at $131.08 million. These figures indicate a challenging quarter characterized by high operational costs or one-time charges despite strong top-line growth, contrasting with the positive analyst sentiment outlined in the forward-looking analysis.

Additional News

Mirum Pharmaceuticals continues to focus on its lead product, LIVMARLI, for rare liver diseases. Recent analyst coverage highlights ongoing interest in the company's commercial execution. Institutional ownership remains robust, with major holders including Eventide Asset Management LLC and BlackRock Inc. maintaining significant positions. Insider activity has been mixed, with some executives buying shares while others sold, reflecting varied internal perspectives. The company maintains its headquarters in Foster City, California, and employs over 200 staff. No new M&A activities or product launches were reported in the immediate pre-earnings window, with market attention centered on the upcoming Q2 financial disclosure and guidance updates regarding LIVMARLI's adoption in key markets.

Summary & Outlook

Mirum exhibits a mixed financial health profile, with strong revenue generation offset by significant net losses in Q1 2026. The growth catalyst is primarily the commercial expansion of LIVMARLI, supported by a strong "Moderate Buy" analyst consensus and rising price targets from major banks like RBC and Morgan Stanley. However, the substantial Q1 net loss of $-790.15 million presents a near-term risk. The outlook is cautiously bullish, as analyst upgrades suggest confidence in long-term profitability, though investors must monitor Q2 margins closely to validate the path toward sustained net income positivity.